Company intelligence / Profile preview

Sunovion

Marlborough, Massachusetts, United Statesus.sumitomo-pharma.com ↗

Ownership: Private
Employees: ~2000
Development stage: Commercial

Overview

Sunovion developed several approved drugs primarily targeting CNS disorders and respiratory diseases. Its most advanced pipeline assets before merging included ulotaront—a novel TAAR1 agonist with potential applications in schizophrenia, generalized anxiety disorder, and major depressive disorder—and SEP‑4199. Clinical results have shown promise particularly for ulotaront’s efficacy in schizophrenia; further studies are ongoing under the new corporate structure.

Therapeutic areas: PulmonologyPsychiatryNeurologyUrology
Modalities: Small moleculeBiologicCell therapyGene therapy
Industry: Biotech

Drug pipeline

13 assets

eszopiclone

Approved

12 more assets in the full pipeline.

Request access →

Partnerships

Otsuka Pharmaceutical Co., Ltd.PsychoGenics Inc.

Beyond the preview

Go deeper on Sunovion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sunovion.

Explore the full profile